TAU N279K

Tau is a microtubule-associated protein essential for stabilizing the structural scaffolding inside neurons. In Alzheimer's disease and related dementias, tau detaches from microtubules and aggregates into beta-sheet-rich fibrils that accumulate in brain cells [2]. Different tau variants have been associated with various neurodegenerative diseases, with specific mutations affecting tau's propensity to aggregate and cause neuronal dysfunction. The N279K variant involves substitution of asparagine (a polar, uncharged amino acid) with lysine (a positively charged amino acid) at position 279 of the tau protein. This position falls within tau's proline-rich region, which normally mediates protein-protein interactions and influences tau's conformational flexibility. The computational structure prediction of N279K tau yielded an average confidence score (pLDDT) of 54.3, which falls well below the 70 threshold generally considered reliable for structural interpretation. This very low confidence indicates that the predicted structural model contains substantial uncertainty and should not be used to draw firm conclusions about the mutation's structural effects. The low confidence likely reflects intrinsic disorder in tau protein, which lacks a stable folded structure under physiological conditions and instead adopts multiple dynamic conformations [2]. Tau's intrinsically disordered nature makes it particularly challenging for structure prediction algorithms, which are optimized for well-folded proteins. Without experimental validation through techniques like solid-state NMR spectroscopy or cryo-electron microscopy of fibrillar assemblies, the structural impact of N279K remains speculative. Clinical context for this specific variant is limited in the available literature. While tau phosphorylation at various sites serves as a biomarker for Alzheimer's disease diagnosis [1], and tau accumulation drives synapse loss and neurodegeneration in tauopathies [3], the N279K variant has not been extensively characterized in published studies. The introduction of a positive charge at position 279 could theoretically alter tau's interactions with microtubules or influence its aggregation propensity, but experimental studies would be required to test these hypotheses. Future research combining biochemical characterization, aggregation assays, and structural biology techniques would be needed to understand whether N279K contributes to disease pathology.